CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Revenues
Total revenues	$ 13,367,443	$ 18,168,677
Total cost of revenues	7,834,011	13,115,037
Gross profit	5,533,432	5,053,640
Operating expenses:
Selling, general and administrative	12,751,644	15,097,360
Research and development	3,735,078	3,926,043
Total operating expenses	16,486,722	19,023,403
LOSS FROM OPERATIONS	(10,953,290)	(13,969,763)
Interest income	75,332	7,200
Transaction cost allocated to warrant liabilities		(1,668,112)
Unrealized gain on change in fair value of warrants classified as a liability	854,400	17,999,521
Loss on issuance of warrants		(10,591,600)
Other income (expense), net	642	(47,305)
Loss before provision for income taxes	(10,022,916)	(8,270,059)
Provision for income taxes	0	0
NET LOSS	(10,022,916)	(8,270,059)
Less: Net loss attributable to noncontrolling interest	75,857	2,168
NET LOSS attributable to Applied DNA Sciences, Inc.	(9,947,059)	(8,267,891)
Deemed dividend related to warrant modifications		110,105
NET LOSS attributable to common stockholders	$ (9,947,059)	$ (8,377,996)
Net loss per share attributable to common stockholders - basic	$ (0.76)	$ (0.93)
Net loss per share attributable to common stockholders - diluted	$ (0.76)	$ (0.93)
Weighted average shares outstanding - basic	13,075,416	8,967,704
Weighted average shares outstanding - diluted	13,075,416	8,967,704
Product revenues
Revenues
Total revenues	$ 1,218,185	$ 1,882,804
Total cost of revenues	1,308,620	2,116,717
Service revenues
Revenues
Total revenues	996,866	759,138
Clinical laboratory service revenues
Revenues
Total revenues	11,152,392	15,526,735
Total cost of revenues	$ 6,525,391	$ 10,998,320